Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
Reading Hospital & Medical Center
mi
from
West Reading, PA
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
Reading Hospital & Medical Center
mi
from
West Reading, PA
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
CCOP - Main Line Health
mi
from
Wynnewood, PA
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
CCOP - Main Line Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
Sanford Cancer Center
mi
from
Souix Falls, SD
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
Sanford Cancer Center
mi
from
Souix Falls, SD
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
Thompson Cancer Survival Center-Dowell Springs
mi
from
Knoxville, TN
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
Thompson Cancer Survival Center-Dowell Springs
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
MBCCOP, Virginia Commonwealth University
mi
from
Richmond, VA
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
MBCCOP, Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
Puget Sound Oncology Consortium
mi
from
Seattle, WA
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
Puget Sound Oncology Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
CCOP, Virginia Mason
mi
from
Seattle, WA
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
CCOP, Virginia Mason
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
CCOP - Northwest
mi
from
Tacoma, WA
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
Camden-Clark Memorial Hospital
mi
from
Parkersburg, WV
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
Camden-Clark Memorial Hospital
mi
from
Parkersburg, WV
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
Wheeling Hospital
mi
from
Wheeling, WV
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
Wheeling Hospital
mi
from
Wheeling, WV
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
CCOP, Marshfield Clinic
mi
from
Marshfield, WI
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
CCOP, Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated:  8/11/2015
Odette Cancer Centre
mi
from
Toronto,
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status: Enrolling
Updated: 8/11/2015
Odette Cancer Centre
mi
from
Toronto,
Click here to add this to my saved trials
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/11/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/11/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Alaska Regional Hospital Cancer Center
mi
from
Anchorage, AK
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Alaska Regional Hospital Cancer Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Broward General Medical Center Cancer Center
mi
from
Fort Lauderdale, FL
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Broward General Medical Center Cancer Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Northeast Georgia Medical Center
mi
from
Gainesville, GA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Pearlman Comprehensive Cancer Center at South Georgia Medical Center
mi
from
Valdosta, GA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Pearlman Comprehensive Cancer Center at South Georgia Medical Center
mi
from
Valdosta, GA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Reid Hospital & Health Care Services
mi
from
Richmond, IN
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Reid Hospital & Health Care Services
mi
from
Richmond, IN
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Southwest Medical Center
mi
from
Liberal, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Southwest Medical Center
mi
from
Liberal, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Tammy Walker Cancer Center at Salina Regional Health Center
mi
from
Salina, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Tammy Walker Cancer Center at Salina Regional Health Center
mi
from
Salina, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Associates in Womens Health, PA - North Review
mi
from
Wichita, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Associates in Womens Health, PA - North Review
mi
from
Wichita, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Medical Arts Tower
mi
from
Wichita, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Medical Arts Tower
mi
from
Wichita, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
CCOP - Wichita
mi
from
Wichita, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Via Christi Cancer Center at Via Christi Regional Medical Center
mi
from
Wichita, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Via Christi Cancer Center at Via Christi Regional Medical Center
mi
from
Wichita, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Lucille P. Markey Cancer Center at University of Kentucky
mi
from
Lexington, KY
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Lucille P. Markey Cancer Center at University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Boston University Cancer Research Center
mi
from
Boston, MA
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
Saint Joseph Mercy Cancer Center
mi
from
Ann Arbor, MI
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
Saint Joseph Mercy Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/11/2015
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/11/2015
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Click here to add this to my saved trials